Sodium salicylate restores the impaired insulin response to glucose and improves glucose tolerance in heroin addicts.
Plasma glucose, insulin, C-peptide, glucagon and growth hormone responses to intravenous glucose were evaluated in 10 heroin addicts in the basal state and during an infusion of sodium salicylate, an inhibitor of endogenous prostaglandin synthesis. Ten normal subjects, matched for age, sex and weight served as controls. In the basal state, the heroin addicts had markedly reduced insulin responses to intravenous glucose and low glucose disappearance rates (p less than 0.01 vs controls). The infusion of sodium salicylate caused a striking increase of the acute insulin response to intravenous glucose (from 14.5 +/- 4 microU/ml to 88 +/- 11 microU/ml, p less than 0.001) and restored to normal the reduced glucose tolerance (KG from 1.10 +/- 0.1% min-1 to 2.04 +/- 0.19% min-1). Hypoglycemic values were found in all addicts at the end of the test during salicylate infusion. Indomethacin pretreatment in five additional addicts also caused normalization of the impaired insulin responses to the intravenous glucose challenge and restored to normal the reduced glucose disappearance rate. Plasma glucagon and growth hormone levels were normally suppressed by glucose in addicts in basal conditions; sodium salicylate infusion completely overturned these hormonal responses which became positive in the first 15 min following the glucose challenge. These results demonstrate that the two prostaglandin synthesis inhibitors can restore the impaired B-cell response to glucose in heroin addicts to normal, indicating that this response is not lost but is inhibited by heroin itself or by other substances, perhaps by the endogenous prostaglandins.
Giugliano
D
D
Cattedra di Diabetologia e Dietoterapia, Istituto di Medicina Generale, Terapia Medica e Malattie del Metabolismo, Prima Facoltà di Medicina, Napoli, Italy.
Quatraro
A
A
Consoli
G
G
Stante
A
A
Simeone
V
V
Ceriello
A
A
Paolisso
G
G
Torella
R
R
D000293:Adolescent; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D002096:C-Peptide / Q000097:blood; D005260:Female; D005934:Glucagon / Q000097:blood; D005947:Glucose / Q000378:metabolism* / Q000494:pharmacology; D013006:Growth Hormone / Q000097:blood; D006556:Heroin Dependence / Q000097:blood / Q000378:metabolism*; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D007328:Insulin / Q000097:blood / Q000378:metabolism*; D008297:Male; D011448:Prostaglandin Antagonists / Q000494:pharmacology; D012980:Sodium Salicylate / Q000494:pharmacology*
D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D011448:Prostaglandin Antagonists; D013006:Growth Hormone; D005934:Glucagon; D005947:Glucose; D012980:Sodium Salicylate; D007213:Indomethacin